Churchill Hospital, Oxford, United Kingdom
Mark R. Middleton , Philippa Corrie , Stéphane Dalle , Michal Lotem , Ruth Board , Ana Maria Arance Fernández , Frank Meiss , Patrick Terheyden , Ralf Gutzmer , Carmen Loquai , Toby Talbot , Rudolf Herbst , Katharina C. Kaehler , SRIVIDYA KOTAPATI , Trong Kim Le , Jane Brokaw , Amy Pickar Abernethy
Background: IMAGE (ipilimumab: management of advanced melanoma in real practice) is an ongoing multinational, prospective, observational study that assesses the treatment of advanced (unresectable or metastatic) melanoma (MEL) in a real-world setting. Although there are adequate accumulating overall survival (OS) data from randomized controlled trials for patients (pts) diagnosed with advanced MEL, OS data from robust real-world studies are not available. As a result, the IMAGE study evaluated OS in pts with advanced MEL who received ipilimumab (IPI) and non-IPI therapies. Methods: IMAGE included adult pts who were not participating in a clinical trial and received IPI or other non-IPI therapies. Pts were followed from study enrollment (April 2012) to data extraction (November 27, 2015). Data were collected by electronic case report forms. Results: Of the 1,371 pts included in this study, 84% (n = 1,152) received IPI therapy and 16% (n = 219) did not receive IPI at any time during the study period. At study entry, 60% of pts were male, median age was 64 years, mean follow-up was 8 months, 79% were on second or subsequent line of systemic therapy, 97% had distant metastases, and among 94% of pts (n = 1,285) with BRAF testing, 42% (n = 540) expressed the mutation. In non-IPI pts, the most common systemic MEL therapies were dacarbazine (17%), fotemustine (17%), vemurafenib (15%), dabrafenib (13%), and pembrolizumab (9%). Median OS during the study period (study entry to death or censoring at discontinuation, study completion, or data extraction date) was 11 months (95% CI: 10–13) for IPI pts and 9 months (95% CI: 6–11) for non-IPI pts. The OS probability at year 1 was 48% (standard error: 2%) for IPI pts and 41% (standard error: 4%) for non-IPI pts. Conclusions: Although these are interim data and further follow-up analyses will be needed to confirm these findings, the OS results from IMAGE are consistent with those observed in advanced MEL clinical trials showing improved OS with IPI.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Xizhi Wen
2022 ASCO Quality Care Symposium
First Author: Timothy Hanna
2023 ASCO Annual Meeting
First Author: Daniel Olson
2024 ASCO Annual Meeting
First Author: John Gordon Lenehan